Stocktoria
Protalix BioTherapeutics, Inc. PLX
NYSE American · XASE · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2010-09-06
Protalix BioTherapeutics, Inc. institutional holders (13F)
| Investor | Shares | Value | % of company |
|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 1,224,800 | $2.7M | 1.52% |
| BlackRock Finance, Inc. | 333,171 | $389,810 | 0.41% |
| CITADEL ADVISORS LLC | 69,600 | $151,032 | 0.09% |
| AQR CAPITAL MANAGEMENT LLC | 30,493 | $66,169 | 0.04% |
| TWO SIGMA INVESTMENTS, LP | 18,129 | $39,340 | 0.02% |
% of company = reported 13F shares ÷ shares outstanding. Based on the latest filings; not every holder reports every quarter.
Source: SEC EDGAR filings · CIK 0001006281 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.